Palbociclib

Red

Brand Name(s):IBRANCE

Indication:Cancer- breast (HER2-negative locally advanced or metastatic)

Rationale:1,2,3

Considered:Jan-17

Review Date:Jul-26

Comments:
MHRA warns cases of interstitial lung disease and pneumonitis have been reported in patients receiving this CDK4/6 inhibitor. Patients should be advised of the need to seek advice right away if they develop new or worsening respiratory symptoms.

June ’21